No price range yet · latest SEC filing Sep 2, 2026.
Pinch-zoom for details.
Drug developer working on botanical (plant-based) medicines.
Quarter
1st 9 months
Quarter
1st 9 months
Quarter
1st 9 months
| CAD | Q 2025 | Q 2026 | Change | 9M 2025 | 9M 2026 | Change |
|---|---|---|---|---|---|---|
| Revenue | 7.36M | 177K | −97.6% | 22.3M | 1.72M | −92.3% |
| Operating result | (34.7K) | (1.94M) | −5,499% | (586K) | (5.79M) | −888% |
| Net result | (4.80M) | (1.94M) | +59.6% | (5.64M) | (5.74M) | −1.8% |
| CAD | Q 2025 | Q 2026 | Change |
|---|---|---|---|
| Revenue | 7.36M | 177K | −97.6% |
| Operating result | (34.7K) | (1.94M) | −5,499% |
| Net result | (4.80M) | (1.94M) | +59.6% |
| CAD | 9M 2025 | 9M 2026 | Change |
|---|---|---|---|
| Revenue | 22.3M | 1.72M | −92.3% |
| Operating result | (586K) | (5.79M) | −888% |
| Net result | (5.64M) | (5.74M) | −1.8% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing doesn't set out its risks in a list we could read.
The filing doesn't set out its strategy in a list we could read.
Source: Devonian Health Group Inc.'s Form F-1/A, filed with the SEC on Sep 2, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back